Figure 5. FasL-deficient DO11 T cells fail to induce skin lesions.

DO11 or DO11^gld T cell–injected Dox/400R TLR9^WT or TLR9^KO Ii-TGO recipients were evaluated 4 weeks after injection. (A) Clinical appearance (upper row) and skin histology by H&E staining. Original magnification, ×100 (middle row); ×200 magnification (bottom row). Representative images from n = 5 mice per group. (B) Spleen weights. (C) Skin-infiltrating cells, percentages of CD45⁺ cells in total skin cell suspension (left); percentages of CD11b⁺ myeloid cells, CD11b⁺Ly6C⁺ inflammatory monocytes, and CD11b⁺Ly6G⁺ neutrophils (center); and percentages of CD4⁺, CD4⁺KJ126⁺, and KJ126⁺IFN-γ⁺ T cells (right) within the CD45⁺ gate. (D) Autoantibodies detected by HEp2 staining and ANA score. Original magnification, ×200. Data are shown as mean ± SEM and are representative of 2 independent experiments with n = 8 mice per group. *P < 0.01; **P < 0.01; ***P < 0.001; ****P < 0.0001, 1-way ANOVA and 2-way ANOVA with Šidák’s multiple-comparison test.